Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05350501 · ClinicalTrials.gov registry record · Phase 2
EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer
A Phase 2 study, sponsored by Enterome.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT05350501: Clinical Trial Phase 2 study, sponsored by Enterome.
NCT05350501 is a Phase 2 study that was terminated before completion, run by Enterome. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05350501, a Phase 2 study, was terminated before completion, sponsored by Enterome.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or IV after completion of standard curative therapy.
Primary Outcome
Percentage of patients with ctDNA clearance and no radiographic evidence of recurrence
Interventions
- DRUG EO2040
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-03-01 |
| Est. Completion | 2024-01-23 |
| Phase | Phase 2 |
Why NCT05350501 stopped before completion
NCT05350501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which EO2040 is the first listed.
NCT05350501 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05350501 about?
NCT05350501 is a clinical study titled "EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer". The current study will evaluate the microbiome-derived therapeutic vaccine EO2040 in combination with nivolumab in patients with circulating tumor DNA-defined Minimal Residual Disease (MRD) of colorectal cancer stage II, III, or IV after completion of standard curative therapy.
What is the current status of trial NCT05350501?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2023-03-01. Estimated completion is 2024-01-23.
What interventions are being tested in trial NCT05350501?
The interventions under investigation include: EO2040 (DRUG).
Who is sponsoring clinical trial NCT05350501?
This trial is sponsored by Enterome, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05350501's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI